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A case-control study of influenza vaccine effectiveness 
among Malaysian pilgrims attending the Haj in 
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Objectives: To determine influenza vaccine effectiveness against clinically defined influenza-like illness among 
Malaysian pilgrims attending the Haj in Saudi Arabia. 
Methods: During February and March 2000, the authors conducted an unmatched case-control study. Case patients 
were identified at one of five hotel clinics, while controls were residents of these hotels who had not attended a clinic. 
Results: Among 820 case patients-84% of whom had received antibiotics-and 600 controls, the adjusted vaccine 
effectiveness against clinic visits for influenza-like illness was 77% (95% confidence interval: 69,83), and that against 
receipt of antibiotics was 66% (95% confidence interval, 54,75). The vaccine did not prevent clinic visits for non- 
influenza-like upper respiratory tract illness (adjusted vaccine effectiveness, 20%; 95% confidence interval: -24,49). 
Conclusions: Influenza vaccine was effective in preventing clinic visits for influenza-like illness and antibiotic use. 
Pilgrims traveling to the Haj in Saudi Arabia should consider influenza vaccination use. 
Int J Infect Dis 2003; 7: 210-214 
INTRODUCTION 
Each year, approximately 2 000 000 pilgrims travel to 
Saudi Arabia to perform the Haj, one of the five pillars 
of Islam. People from around the world gather in 
crowded conditions where the risk of disease trans- 
mission is high. Previous studies have documented that 
pilgrims returning from the Haj contribute to the world- 
wide spread of meningococcal diseasel” and possibly 
cholera.4 Few studies, however, have examined respira- 
tory illness among pilgrims.5 
We conducted an unmatched retrospective case- 
control study to determine influenza vaccine effective- 
ness among Malaysian pilgrims attending the Haj. 
Vaccine effectiveness, rather than efficacy, was measured, 
since our study relied on data gathered from routine 
population-based influenza vaccination rather than from 
investigator-determined vaccine distribution. Because 
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laboratory-based methods for documenting influenza 
illness were not available to us, we determined vaccine 
effectiveness against clinically defined influenza-like 
illness. 
MATERIALS AND METHODS 
Vaccine administration and type 
During the 2000 Haj, the Malaysian Haj Authority 
recommended that all pilgrims receive influenza vaccine. 
Unlike meningococcal vaccine, however, influenza 
vaccine was not compulsory. Influenza vaccine was 
administered like other vaccines received for the Haj, 
and given at special Haj immunization clinics or by 
private health care providers. 
During 1999-2000, almost all influenza vaccine sold 
in Malaysia was Vaxigrip, manufactured by Aventis 
Pasteur (Lyon, France) (formerly Pasteur Merieux 
Connaught). Specific components included: 
A/Sidney/5197 (HjNz)-like strain (A/Sidney/5197 
(IVR-108)) 15 ug hemagglutinin 
A/Beijing/262195 (HiNi)-like strain (A/Beijing/ 
262195 (X-127)) 15 ,ug hemagglutinin 
BlBeijingl184/93-like strain (BlYamanashill66l98, 
15 ug hemagglutinin 
The World Health Organization maintains a worldwide 
influenza surveillance system. Saudi Arabia did not 
participate in this system during the study period. 
During December 1999 through February 2000, 10 of 
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13 influenza isolates reported from Kuala Lumpur, 
Malaysia were type A (H~Nz,), none were type A (HrNr), 
and three were type B; similarly, the great majority of 
isolates reported from Asia and worldwide were type A 
(HaNz) (World Health Organization Flunet website: 
http://oms2.b3e.jussieu.fr/flunet/activity.html). 
Study subjects and study period 
As in previous years, Malaysian pilgrims were assigned 
to one of 20 equivalent hotels in Mecca rented by the 
Malaysian government. Hotels housed approximately 
2000 persons each. Each hotel contained a clinic, 
primarily for use by hotel residents, but which any 
Malaysian pilgrim could have attended. Pilgrims arrived 
by air in Mecca between 15 February and 8 March. 
Beginning on 15 March, pilgrims left Mecca to travel to 
Arafah to perform the next stage of the Haj. Conse- 
quently, cases and controls were recruited from 15 
February to 14 March. 
Case patient and control definitions and selection 
We arbitrarily selected five hotels in which to conduct 
our study. Case patients were recruited from hotel 
clinics. Patients who presented to the clinic with any 
upper or lower respiratory illness during the study 
period were included, regardless of whether or not they 
met the definition for influenza-like illness. Although 
persons might have attended the clinic on multiple 
occasions, only their first visit was used for analysis. 
Patients presenting for care at hotel clinics did not 
necessarily reside in the hotel but, since each hotel had 
its own clinic, this was usually the case. Influenza-like 
illness was the primary outcome examined. Case 
definitions included the following. 
Influenza-like illness 
This was defined as sore throat in combination with 
either temperature 238.O”C or cough.This definition was 
consistent with other studies using populations com- 
posed primarily of healthy working adults,5m7 although it 
differs from that used by the US Centers for Disease 
Control and Prevention (CDC) (temperature of at least 
37.8”C in combination with either sore throat or cough). 
For comparison purposes, we evaluated vaccine effective- 
ness against both outcomes during univariate analysis. 
Non-influenza-like upper respiratory tract illness 
All case patients enrolled in the study who did not meet 
the definition of influenza-like illness were considered to 
have non-influenza-like upper respiratory tract illness. 
All case patients had one or more symptoms of upper 
respiratory tract illness, including sore throat, fever, 
cough, nasal congestion, malaise, headache, or muscle 
ache. 
Antibiotic and non-prescription medication use 
This was defined as acquisition of medication at one of 
the study clinics. Approximately 18 oral and 11 
injectable antibiotics were available at the clinic. Some 
pilgrims brought their own antibiotics and other 
medications from Malaysia, but this information was not 
collected. 
Controls were defined as persons living in one of the 
five study hotels who had not attended any clinic. To 
ascertain that potential controls had not attended a 
clinic, we went from room to room in each of the study 
hotels, and interviewed people; those who reported not 
attending a clinic were asked to participate. To allow 
controls and case patients an equal time period in which 
to have developed illness, controls at a specific hotel 
were identified and interviewed during a single day, that 
being the day on which case enrollment ended for case 
patients. For example, for hotel number 1, case 
enrollment in the clinic ended on 9 March, and controls 
at the hotel were interviewed on 9 March. For hotels two 
to five, the dates for control enrollment were 10 March 
to 14 March, respectively. 
We had planned to recruit approximately one 
unmatched control for every case patient identified, 
regardless of whether or not the case patient met the 
definition of influenza-like illness. Because of time 
and personnel constraints, however, only a fraction of the 
desired number of controls was enrolled at three of the 
five study hotels. We chose to control for age and gender 
during analysis rather than matching for these variables 
during enrollment, because of the considerable logistic 
difficulties that we would have encountered in identify- 
ing appropriate matched controls. 
We did not attempt to determine whether or not 
controls had an upper respiratory illness that did not 
result in a clinic visit, since we believed that this 
information would be subject to substantial recall bias, 
and would not be comparable to the data collected from 
case patients. By contrast, we believed that controls 
could easily recall a clinic visit during approximately the 
previous month. 
Data collection 
We collected clinical information for case patients, and 
background information-including influenza vaccina- 
tion status, age, gender, and hotel-for both case 
patients and controls using’ a standardized reporting 
form. Because of the requirement for meningococcal 
vaccination before entry into Saudi Arabia, pilgrims 
generally carried vaccination cards. Persons were 
considered vaccinated if they had one of these cards 
and it documented influenza vaccination during the 
3 months before the beginning of the 2000 Haj. For 
people who did not have a card, we accepted a verbal 
history. 
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Analysis and power 
Data were entered into two databases, one for those 
recruited at the clinics, and one for controls recruited in 
their hotel rooms. Databases were merged by linking on 
pilgrims’ passport numbers. Vaccine effectiveness was 
calculated as: (l-odds ratio for vaccination) x100. 
We conducted a multiple logistic regression analysis 
to adjust for gender and age. Additionally, although cases 
and controls were recruited from the same hotels, we also 
included hotel in the model because of incomplete ascer- 
tainment of controls. Gender was entered as a dicho- 
tomous variable, age as a linear variable, and hotel 
number as a categorical variable with each of the first four 
hotels compared to the last hotel (arbitrarily defined). 
Because of the relatively small number of variables 
compared to the sample size, all variables were included 
in the final models. All analyses were conducted with 
SPSS statistical software, version 9.0 (SPSS Inc., 1998). 
For influenza-like illness (the primary outcome of 
interest), we identified 820 cases. Additionally, 600 
controls were identified. Given this sample size, for an 
alpha error of 5% and a vaccine exposure among 
controls of 88%, we had 80% power to detect a vaccine 
effectiveness of 36% or greater. 
RESULTS 
Univariate analysis 
We identified 1310 persons who had a clinic visit for 
upper respiratory tract symptoms at the five clinics, 
of whom 63% had influenza-like illness, 14% had 
influenza by the CDC definition, 98% received an over- 
the-counter medication, and 78% received an anti- 
biotic. Of the 820 persons with influenza-like illness, 
99% received an over-the-counter medication, and 84% 
received an antibiotic. Only four patients in our study 
were referred to the hospital, since most seriously ill 
persons went directly to the hospital without first pre- 
senting to a hotel clinic. Regardless of the outcome 
analyzed, case patients and controls differed by gender, 
age, and hotel (Table l), suggesting that these factors 
might be confounders. 
The vaccination rate among case patients was 63%, 
compared to 88% among controls. The observed vaccine 
effectiveness was 78% against clinic visits for influenza- 
like illness and 66% against clinic visits for influenza 
using the CDC definition (Table 2). By contrast, the 
observed vaccine effectiveness was -14% against clinic 
visits for non-influenza-like upper respiratory tract 
illness. 
Vaccine was also effective in preventing receipt of 
antibiotics and over-the-counter medications from 
the clinics (Table 2), an expected finding, since most 
case patients received both categories of medication. 
Observed vaccine effectiveness was greater than 65% 
for four of the study hotels but was -18% (95% con- 
fidence interval: -116,36) at the fifth; the proportion of 
upper respiratory illness due to influenza-like illness was 
84-100% at the first four hotels, compared to 58% at the 
fifth. Persons at the fifth hotel did not differ from those 
at the other hotels with respect to age, gender, or vaccine 
receipt. 
Table 1. Potential confounding factors in a study of influenza vaccine effectiveness among Malaysian pilgrims attending the 2000 
Haj in Saudi Arabia 
Risk factora Controls Influenza-like 
illness b 
Non-influenza-like 
upper respiratory 
tract illnessc 
Influenza by 
CDC 
definitiond 
Gender 
Male 
Female 
Odds ratio 
95% Cl 
Age ~60 years 
Yes 
No 
Odds ratio 
95% Cl 
Hotele 
2 
3 
4 
5 
198 
399 
387 
210 
102 295 57 
127 108 11 
63 114 21 
91 179 0 
217 124 90 
367 199 78 
425 269 96 
1.7 1.5 1.6 
1.4, 2.2 1.2, 1.9 1.2, 2.3 
57s 313 126 
231 160 50 
1.4 1.1 1.4 
1.1, 1.7 0.82, 1.4 0.95, 2.0 
83 
22 
107 
165 
113 
a In rare instances, gender and age were not filled in on the questionnaire for case patients or controls. 
b Influenza-like illness: sore throat in combination with either temperature 238.O”C or cough. 
c Non-influenza-like upper respiratory tract illness: case patients who did not meet the definition of influenza-like illness and had sore throat, fever, 
cough, nasal congestion, malaise, headache, or muscle ache. 
d Influenza according to US Centers for Disease Control and Prevention definition: temperature of at least 37.8”C in combination with either sore 
throat or cough. 
eFor case patients, hotel refers to the hotel at which they attended a clinic, while for controls, hotel refers to the hotel of residence during the Haj. 
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Table 2. Influenza vaccine effectiveness from a case-control study among Malaysian pilgrims attending the 2000 Haj in Saudi Arabia 
Controls~ Influenza-like 
illness b 
Non-influenza-like 
upper respiratory 
tract ilInes 
Influenza by 
CDC 
definitiond 
Received 
antibiotics 
at the 
clinic 
Received over 
the counter 
medications 
at the clinic 
N (% vaccinated) 
Observed vaccine 
effectiveness= 
(95% confidence 
interval) 
600 (88) 820 (63) 490 (90) 179 (72) 1016 (71) 1286 (72) 
78% -14% 66% 67% 65% 
(71, 83) (-67, 22) (4% 87) (57, 75) (54, 74) 
Adjusted vaccine 
effectivenessf 
(95% confidence 
interval) 
77% 20% 71% 66% 64% 
(6% 83 (-24, 49) (53, 82) (54, 75) (52, 74) 
a Each of the five dichotomous outcome variables was compared to the same group of controls. 
b Influenza-like illness: sore throat in combination with either temperature Z38.O”C or cough. 
c Non-influenza-like upper respiratory tract illness: case patients who did not meet the definition of influenza-like illness and had sore throat, fever, 
cough, nasal congestion, malaise, headache, or muscle ache. 
d Influenza according to US Centers for Disease Control and Prevention definition: temperature of at least 37.8”C in combination with either sore 
throat or cough. 
e Vaccine effectiveness = (l-odds ratio). 
f Adjusted for age, gender, and hotel. 
Multivariate analysis 
For the two definitions of influenza analyzed, we created 
a multiple logistic regression model, entering simultane- 
ously vaccine status, gender, age, and hotel. The adjusted 
vaccine effectiveness was 77% (95% confidence interval: 
69, 83) against inlluenza-like illness and 71% (95% 
confidence interval: 53,82) against influenza according to 
the CDC definition (Table 2). Similar to the results 
obtained from univariate analysis, vaccination did not 
prevent non-influenza-like upper respiratory tract illness. 
If influenza vaccine decreases the inappropriate use 
of antibiotics at the Haj, it may lead to a decrease in the 
worldwide distribution of antibiotic-resistant organisms. 
Although no studies have examined the contribution of 
Haj pilgrims to the transmission of antibiotic-resistant 
organisms, some studies have documented the ease with 
which antibiotic-resistant pneumococcal clones can 
spread. l”,ll Additional studies, including some per- 
formed during the 2000 Haj, have documented the 
initiation of meningococcal outbreaks following the 
return of pilgrims to their home countries.1-3 
DISCUSSION 
We found that vaccine was effective in preventing clinic 
visits for influenza-like illness among Malaysian pilgrims 
attending the 2000 Haj in Saudi Arabia. These results 
support an earlier study reporting similar findings 
among Pakistani pilgrims attending the 1999 Haj,5 and 
add to the relatively sparse data on influenza vaccine 
efficacy or effectiveness among populations composed 
largely of healthy working adults.6>7 In addition to 
preventing clinic visits for influenza, vaccine was also 
effective in preventing the dispensing of over-the- 
counter medications and antibiotics, since almost all 
persons who presented to a clinic with influenza-like 
illness received both of these categories of drugs. 
Influenza vaccine effectiveness in our study was 
higher than that reported previously.5-7J2 The reasons 
for this are unclear. An influenza outbreak may have 
occurred among Malaysian pilgrims during the 2000 
Haj if a large proportion of pilgrims had inadequate 
immunity to circulating strains. Alternatively, the lack of 
outbreaks from other causes of upper respiratory infec- 
tion could also have increased vaccine effectiveness. 
Either explanation is consistent with our finding that the 
only hotel in which vaccine was not effective had a high 
proportion of non-influenza-like respiratory illness. 
Additionally, our relatively high reported effectiveness 
may have resulted from the biases inherent in the 
case-control designI since previous studies have 
tended to use the cohort method. 
To the extent that influenza vaccine can decrease The major limitation of the current study was that it 
clinic visits, it may result in substantial savings to the was non-randomized and non-blinded. Consequently, it 
health care system. These savings could accrue to the is possible that persons who reported receiving vaccine 
pilgrims and their governments in instances where the were less likely than unvaccinated persons to present to 
pilgrims’ countries provide direct medical care in Saudi a clinic and more likely to take measures to prevent 
Arabia, such as with Malaysia. Alternatively, for pilgrims illness. If this were a major factor, however, it is probable 
who depend on locally financed medical care, influenza that vaccine would have shown effectiveness against 
vaccine may result in substantial savings to the Saudi both influenza-like and non-influenza-like illness. In this 
Arabian government. Studies in industrialized countries context, it is somewhat reassuring that vaccine was not 
have found that influenza vaccine is one of the most effective against non-influenza-like upper respiratory 
cost-effective public health measures known.s9 tract illness. Our study was also limited by our inability 
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to calculate attack rates and by a limited questionnaire, 
which did not allow us to evaluate potential confound- 
ing factors such as pre-existing illness and smoking 
history. Finally, we estimated vaccine effectiveness against 
clinic visits for influenza-like illness but not against all 
influenza-like illnesses. The former may represent much 
of the cost and relatively severe illness associated with 
influenza but does not reflect the overall disease burden. 
Approximately 2 000 000 pilgrims a year travel to 
Saudi Arabia to attend the Haj. Because of the close 
contact that pilgrims have with each other, widespread 
antibiotic use, and the international nature of the Haj, 
ample opportunity exists for disease transmission, 
development of antibiotic resistance, and worldwide 
dissemination of disease-causing organisms. The current 
study suggests that influenza vaccine may partially 
address these concerns. As with a previous study among 
Haj pilgrims,5 we recommend that governments with 
substantial numbers of Haj attendees support influenza 
immunization programs for pilgrims, and that the Saudi 
government consider requiring influenza vaccination for 
all pilgrims before entrance into Mecca or Medina. 
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